Arialys Therapeutics, a pre-clinical stage company, was founded to explore the latest discoveries in autoimmune neuropsychiatry. The company's core mission is to develop precision medicines that block pathogenic autoantibodies in the brain, addressing severe neurological and psychiatric diseases. Arialys Therapeutics focuses on how the immune system impacts central nervous system (CNS) health, disease, and treatment, aiming to expand therapeutic options for autoimmune neuropsychiatric conditions.

Notable affiliated individuals and investors include experts in neuroscience and immunology, though specific names are not provided. Key achievements include advancing the understanding of immune cell-produced autoantibodies in the brain and developing targeted therapies to mitigate their effects. Arialys Therapeutics' impact lies in its potential to revolutionize treatment approaches for autoimmune neuropsychiatric diseases, offering new hope for patients with these challenging conditions.